Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2010 1
2011 4
2012 4
2013 2
2014 2
2015 4
2016 2
2017 6
2018 5
2019 8
2020 10
2021 15
2022 12
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, Ciardiello D, Terminiello M, Borrelli C, Vitiello PP, De Braud F, Morano F, Avallone A, Normanno N, Nappi A, Maiello E, Latiano T, Falcone A, Cremolini C, Rossini D, Santabarbara G, Pinto C, Santini D, Cardone C, Zanaletti N, Di Liello A, Renato D, Esposito L, Marrone F, Ciardiello F. Martinelli E, et al. Among authors: latiano t. JAMA Oncol. 2021 Oct 1;7(10):1529-1535. doi: 10.1001/jamaoncol.2021.2915. JAMA Oncol. 2021. PMID: 34382998 Free PMC article. Clinical Trial.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Among authors: latiano tp. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer.
Ciardiello D, Martini G, Famiglietti V, Napolitano S, De Falco V, Troiani T, Latiano TP, Ros J, Elez Fernandez E, Vitiello PP, Maiello E, Ciardiello F, Martinelli E. Ciardiello D, et al. Among authors: latiano tp. Cancers (Basel). 2021 Apr 17;13(8):1941. doi: 10.3390/cancers13081941. Cancers (Basel). 2021. PMID: 33920531 Free PMC article. Review.
Immunotherapy in advanced anal cancer: Is the beginning of a new era?
Ciardiello D, Guerrera LP, Maiorano BA, Parente P, Latiano TP, Di Maio M, Ciardiello F, Troiani T, Martinelli E, Maiello E. Ciardiello D, et al. Among authors: latiano tp. Cancer Treat Rev. 2022 Apr;105:102373. doi: 10.1016/j.ctrv.2022.102373. Epub 2022 Mar 8. Cancer Treat Rev. 2022. PMID: 35279535 Review.
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo.
Massimino L, Palmieri O, Facoetti A, Fuggetta D, Spanò S, Lamparelli LA, D'Alessio S, Cagliani S, Furfaro F, D'Amico F, Zilli A, Fiorino G, Parigi TL, Noviello D, Latiano A, Bossa F, Latiano T, Pirola A, Mologni L, Piazza RG, Abbati D, Perri F, Bonini C, Peyrin-Biroulet L, Malesci A, Jairath V, Danese S, Ungaro F. Massimino L, et al. Among authors: latiano t. Gut. 2023 Oct;72(10):1838-1847. doi: 10.1136/gutjnl-2022-328375. Epub 2023 Feb 14. Gut. 2023. PMID: 36788014 Free PMC article.
The potential role of nintedanib in treating colorectal cancer.
Rossi A, Latiano TP, Parente P, Chiarazzo C, Limosani F, Di Maggio G, Maiello E. Rossi A, et al. Among authors: latiano tp. Expert Opin Pharmacother. 2017 Aug;18(11):1153-1162. doi: 10.1080/14656566.2017.1346086. Epub 2017 Jul 6. Expert Opin Pharmacother. 2017. PMID: 28649871 Review.
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
Moretto R, Germani MM, Giordano M, Conca V, Proietti A, Niccoli C, Pietrantonio F, Lonardi S, Tamburini E, Zaniboni A, Passardi A, Latiano TP, Fanotto V, Di Donato S, Prisciandaro M, Bergamo F, Masi G, Fontanini G, Ugolini C, Cremolini C. Moretto R, et al. Among authors: latiano tp. Br J Cancer. 2023 Mar;128(7):1391-1399. doi: 10.1038/s41416-023-02180-7. Epub 2023 Feb 9. Br J Cancer. 2023. PMID: 36759721 Free PMC article. Clinical Trial.
Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model.
Panebianco C, Pisati F, Villani A, Andolfo A, Ulaszewska M, Bellini E, Ferro C, Lombardi R, Orsenigo F, Latiano TP, Belmonte B, Tripodo C, Perri F, Pazienza V. Panebianco C, et al. Among authors: latiano tp. Cell Death Discov. 2023 Apr 5;9(1):116. doi: 10.1038/s41420-023-01397-y. Cell Death Discov. 2023. PMID: 37019893 Free PMC article.
Chemokine receptor CXCR4: role in gastrointestinal cancer.
Lombardi L, Tavano F, Morelli F, Latiano TP, Di Sebastiano P, Maiello E. Lombardi L, et al. Among authors: latiano tp. Crit Rev Oncol Hematol. 2013 Dec;88(3):696-705. doi: 10.1016/j.critrevonc.2013.08.005. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2013. PMID: 24120239 Review.
75 results